Robert M Berman

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study
    Robert M Berman
    Bristol Myers Squibb Co, Wallingford, Conn 06492, USA
    J Clin Psychiatry 68:843-53. 2007
  2. pmc Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
    Robert M Berman
    Neuroscience Global Clinical Research Bristol Myers Squibb, Wallingford, CT, USA
    Neuropsychiatr Dis Treat 7:303-12. 2011
  3. ncbi Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants
    Robert M Berman
    Neuroscience Global Clinical Research at Bristol Myers Squibb, Wallingford, CT 06492, USA
    CNS Spectr 14:197-206. 2009
  4. doi The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study
    Ronald N Marcus
    Bristol Myers Squibb, Wallingford, CT 06492, USA
    J Clin Psychopharmacol 28:156-65. 2008
  5. ncbi Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response
    Gerard Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    Neuropsychopharmacology 29:1166-71. 2004
  6. doi Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy
    James Craig Nelson
    Department of Psychiatry, University of California San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA
    Int Clin Psychopharmacol 27:125-33. 2012
  7. ncbi A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine
    John W Newcomer
    Department of Psychiatry, Psychology and Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Psychiatry 69:1046-56. 2008
  8. ncbi Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease
    Joseph H Friedman
    Parkinson Disease and Movement Disorders Center, NeuroHealth, Warwick, Rhode Island 02886, USA
    Mov Disord 21:2078-81. 2006
  9. ncbi Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial
    Edward B Perry
    Department of Psychiatry, VA Connecticut Healthcare System, Psychiatry Service 116A, 950 Campbell Avenue, West Haven, CT 06516, USA
    J Clin Psychiatry 65:238-43. 2004
  10. ncbi Cerebrovascular reactivity following administration of mirtazapine in healthy probands--a randomized, placebo controlled double-blind clinical study
    Peter Neu
    Department of Psychiatry, Charite Berlin, Campus Benjamin Franklin, Klinik und Poliklinik fur Psychiatrie und Psychotherapie, Eschenallee 3, 14050 Berlin, Germany
    J Psychiatr Res 40:349-52. 2006

Collaborators

Detail Information

Publications16

  1. ncbi The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study
    Robert M Berman
    Bristol Myers Squibb Co, Wallingford, Conn 06492, USA
    J Clin Psychiatry 68:843-53. 2007
    ....
  2. pmc Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
    Robert M Berman
    Neuroscience Global Clinical Research Bristol Myers Squibb, Wallingford, CT, USA
    Neuropsychiatr Dis Treat 7:303-12. 2011
    ..Effective management of major depressive disorder often includes the long-term use of multiple medications, and the longer-term utility and safety of adjunctive aripiprazole has not been evaluated in a controlled setting...
  3. ncbi Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants
    Robert M Berman
    Neuroscience Global Clinical Research at Bristol Myers Squibb, Wallingford, CT 06492, USA
    CNS Spectr 14:197-206. 2009
    ..This trial evaluated the efficacy and safety of adjunctive aripiprazole versus antidepressant monotherapy in patients with MDD and independently replicated the positive findings of two similar trials...
  4. doi The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study
    Ronald N Marcus
    Bristol Myers Squibb, Wallingford, CT 06492, USA
    J Clin Psychopharmacol 28:156-65. 2008
    ..1%] vs adjunctive aripiprazole [3.7%]). Aripiprazole is an effective and safe adjunctive therapy as demonstrated in this short-term study for patients who are nonresponsive to standard ADT...
  5. ncbi Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response
    Gerard Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    Neuropsychopharmacology 29:1166-71. 2004
    ..The addition of the alpha2-antagonist yohimbine to fluoxetine appears to hasten the antidepressant response. There is also a trend suggesting an increased percentage of responders to the combined treatment at the end of the 6-week trial...
  6. doi Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy
    James Craig Nelson
    Department of Psychiatry, University of California San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, USA
    Int Clin Psychopharmacol 27:125-33. 2012
    ..12%, respectively, P<0.0001). The numbers needed to treat with aripiprazole+ADT were six for response and eight for remission. Aripiprazole augmentation had a rapid and clinically meaningful effect in ADT minimal responders...
  7. ncbi A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine
    John W Newcomer
    Department of Psychiatry, Psychology and Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Psychiatry 69:1046-56. 2008
    ..This multicenter, randomized, double-blind study compared the metabolic effects of aripiprazole versus olanzapine in overweight persons with schizophrenia or schizoaffective disorder who were previously on olanzapine treatment...
  8. ncbi Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease
    Joseph H Friedman
    Parkinson Disease and Movement Disorders Center, NeuroHealth, Warwick, Rhode Island 02886, USA
    Mov Disord 21:2078-81. 2006
    ..While some patients had a favorable response, aripiprazole was associated with an exacerbation of motor symptoms. In this small study on psychosis in PD, aripiprazole did not appear promising...
  9. ncbi Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial
    Edward B Perry
    Department of Psychiatry, VA Connecticut Healthcare System, Psychiatry Service 116A, 950 Campbell Avenue, West Haven, CT 06516, USA
    J Clin Psychiatry 65:238-43. 2004
    ..Here, we report on a double-blind, randomized, controlled 6-week study of pindolol augmentation of selective serotonin reuptake inhibitors (SSRIs) in depressed outpatients resistant to SSRI monotherapy...
  10. ncbi Cerebrovascular reactivity following administration of mirtazapine in healthy probands--a randomized, placebo controlled double-blind clinical study
    Peter Neu
    Department of Psychiatry, Charite Berlin, Campus Benjamin Franklin, Klinik und Poliklinik fur Psychiatrie und Psychotherapie, Eschenallee 3, 14050 Berlin, Germany
    J Psychiatr Res 40:349-52. 2006
    ..We therefore investigated the influence that antidepressant administration might have on CVR in humans...
  11. ncbi Lifelong course of positive and negative symptoms in chronically institutionalized patients with schizophrenia
    Branislav Mancevski
    Department of Neuroscience, New York State Psychiatric Institute, New York, NY, USA
    Psychopathology 40:83-92. 2007
    ..We sought to describe this course, and to determine the influences of sex, age of onset, and treatment on its evolution...
  12. ncbi Sex differences in diencephalon serotonin transporter availability in major depression
    Julie K Staley
    Department of Psychiatry, Yale University School of Medicine and West Haven VA Connecticut Health Care System, CT 06516, USA
    Biol Psychiatry 59:40-7. 2006
    ..The present study evaluated if previous findings that demonstrated decreased 5-hydroxytryptamine (5-HT) transporter availability in depressed patients would be confirmed in a larger sample and also evaluated sex differences...
  13. pmc Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression
    J Douglas Bremner
    Department of Psychiatry, Emory Center for Positron Emission Tomography, Emory University School of Medicine, Atlanta, GA, USA
    JAMA 289:3125-34. 2003
    ....
  14. ncbi Increased cortical GABA concentrations in depressed patients receiving ECT
    Gerard Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    Am J Psychiatry 160:577-9. 2003
    ..The purpose of this study was to determine if cortical GABA concentrations increase following a course of ECT...
  15. ncbi Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression
    Nashaat N Boutros
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
    Psychiatry Res 113:245-54. 2002
    ..The duration of the therapeutic effects of rTMS delivered to the left prefrontal cortex using the above-described parameters is highly variable...
  16. ncbi Monoamine depletion in unmedicated depressed subjects
    Robert M Berman
    Abraham Ribicoff Center Clinical Neuroscience Research Unit of the Connecticut Mental Health Center, New Haven, Connecticut, USA
    Biol Psychiatry 51:469-73. 2002
    ..This study assesses the integrated role of these monoamine systems in depressed patients...